PDS Biotech Announces Preliminary Biomarker Study Results In Subset Of Advanced HPV-Positive Head And Neck Cancer Patients At ESMO
Portfolio Pulse from Happy Mohamed
PDS Biotechnology Corporation (NASDAQ:PDSB) announced preliminary results from a subset of patients in a Phase 2 clinical trial (VERSATILE-002) evaluating the safety and efficacy of PDS0101 in combination with Merck's KEYTRUDA® in patients with HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma. The data suggests that the combination of PDS0101 and KEYTRUDA® may promote a TH1 predominant cytokine profile associated with improved killer T cell activity and anti-tumor activity.
October 23, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PDS Biotech's preliminary results from a Phase 2 trial of PDS0101 and Merck's KEYTRUDA® show potential for improved killer T cell activity and anti-tumor activity in HPV16-positive cancer patients.
The preliminary results from the Phase 2 trial are promising, suggesting that the combination of PDS0101 and KEYTRUDA® may improve killer T cell activity and anti-tumor activity in HPV16-positive cancer patients. This could potentially lead to a positive impact on PDS Biotech's stock in the short term as it indicates progress in their clinical trials and potential for future success.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100